PRALUENT (alirocumab), lipid-lowering agent, anti-PCSK9

• PRALUENT has Marketing Authorisation in primary hypercholesterolaemia (heterozygous familial or non-familial) or mixed dyslipidaemia.
• The efficacy of PRALUENT was evaluated only in the reduction of one biological criteria, LDL-C level. To date, there is no data justifying the efficacy of alirocumab in terms of morbidity and mortality.
• There remain uncertainties as to alirocumab’s adherence and safety, especially on neurocognitive functions, the risk of development of antibodies and liver safety.

-